PHF TAU IN NEURODEGENERATIVE DISEASE IN MICRONESIA

密克罗尼西亚 PHF TAU 与神经退行性疾病的关系

基本信息

  • 批准号:
    6299377
  • 负责人:
  • 金额:
    $ 21.16万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-03-01 至 2001-02-28
  • 项目状态:
    已结题

项目摘要

The prevalence of neurodegenerative disorders similar to Alzheimer's disease (AD), Parkinson's disease (PD) and Amyotrophic Lateral Sclerosis (ALS) is unusually high among Chamorros in the Mariana Islands. Despite similarities between these Chamorro diseases (known as Guam ALSIPDC) and AD, PD or ALS elsewhere, the predominant findings in Guam ALS/PDC brains are abundant neurofibrillary tangles (NE;Ts) like those in classic AD. For example, the major structural elements of NFTs AD and Guam ALS/PDC are paired helical filaments (PHFs), and previous studies showed that the PHFs in AD and Guam ALSIPDC are formed from abnormally phosphorylated tau proteins (PHFtau). Although, we showed that biopsy derived normal adult human tau is phosphorylated at nearly all of the sites previously identified in AD PHFtau, albeit to a lesser extent, biopsy derived normal human tau undergoes rapid and selective dephosphorylation at sites that are abnormally retained in PHFtau. We also provided data to suggest that differences in the phosphorylation state of normal human tau versus PHFtau may be due to impaired phosphatase activity in the AD brain. Indeed, protein phosphatase 2A (PP2A) was implicated in the failure of PHFtau to undergo efficient dephosphorylation. Since PP2A dephosphorylates tau, alterations in the accessory, catalytic and regulatory subunits of PP2A could play a central role in the generation of PHFtau. Although the degeneration of neurons in Guam ALSIPDC is associated almost exclusively with the accumulation of NFTs, and the levels of tan in the cerebrospinal fluid (CSF) of AD patients are elevated relative to controls, the pathogenesis and biological significance of accumulations of PHFtau in neurofibrillary lesions in AD and Guam ALS/PDC are poorly understood. Thus, Project 4 will test the hypothesis that PHFtau-rich neurofibrillary lesions play a role in the degeneration of neurons in Guam ALS/PDC. To accomplish this, we will assess the biological significance of elevated levels of CSF tan, examine the role of PP2A in the pathogenesis of PHFtau and tangle formation, and characterize the molecular profile of tangle bearing versus normal neurons in the brains of patients with and without Guam ALS/PDC. These studies will provide important insights into the pathogenesis of PHFtau in the hallmark lesions of Guam ALS/PDC, and clarify how these lesions lead to neuron loss in Guam ALS/PDC.
与阿尔茨海默氏症类似的神经退行性疾病的患病率 帕金森病(PD)和肌萎缩侧索硬化症 (ALS)在马里亚纳群岛的查莫罗人中异常高。尽管 这些查莫罗人疾病(称为关岛ALSIPDC)和 其他地方的AD、PD或ALS,关岛ALS/PDC大脑的主要发现 与经典AD中的神经元缠结(NE;Ts)相似,存在大量神经元缠结。 例如,NFT AD和关岛ALS/PDC的主要结构要素 是成对的螺旋丝(PHF),之前的研究表明, AD和关岛ALSIPDC中的PHF是由异常的 磷酸化tau蛋白(PHFtau)。尽管如此,我们发现活检 衍生的正常成人tau蛋白在几乎所有的 先前在AD PHFtau中鉴定的位点,尽管程度较低, 活组织检查衍生的正常人tau蛋白经历快速和选择性的 在PHFtau中异常保留的位点的去磷酸化。我们 还提供了数据,表明磷酸化的差异, 正常人tau相对于PHFtau的状态可能是由于受损的 AD脑内磷酸酶活性。蛋白磷酸酶2A (PP 2A)与PHFtau未能进行有效的细胞内转录有关。 去磷酸化由于PP 2A使tau蛋白去磷酸化, PP 2A的辅助亚基、催化亚基和调节亚基可能发挥重要作用, 在PHFtau的产生中起重要作用。虽然退化的 关岛的ALSIPDC神经元几乎完全与 NFT的积累和脑脊液中的TAN水平 (CSF)AD患者的发病率相对于对照组升高, 以及PHFtau在小鼠体内积累的生物学意义 对AD和关岛ALS/PDC的神经系统病变了解甚少。 因此,项目4将测试以下假设: 神经元损伤在神经元变性中起作用, 关岛ALS/PDC。为了实现这一目标,我们将评估 CSF tan水平升高的意义,检查PP 2A在 PHFtau和缠结形成的发病机制,并表征 大脑中缠结轴承与正常神经元的分子图谱 有和没有关岛ALS/PDC的患者。这些研究将提供 PHFtau发病机制的重要见解, 关岛ALS/PDC的病变,并阐明这些病变如何导致神经元 关岛ALS/PDC的损失。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

VIRGINIA M LEE其他文献

VIRGINIA M LEE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('VIRGINIA M LEE', 18)}}的其他基金

Pathogenesis of Tauopathies
Tau蛋白病的发病机制
  • 批准号:
    10583338
  • 财政年份:
    2023
  • 资助金额:
    $ 21.16万
  • 项目类别:
Project I "Mechanisms of Pathological aSyn Transmission"
项目一“病理性非同步传播机制”
  • 批准号:
    10373920
  • 财政年份:
    2019
  • 资助金额:
    $ 21.16万
  • 项目类别:
Center On Alpha-synuclein Strains In Alzheimer Disease & Related Dementias
阿尔茨海默病α-突触核蛋白菌株研究中心
  • 批准号:
    10654792
  • 财政年份:
    2019
  • 资助金额:
    $ 21.16万
  • 项目类别:
Project I "Mechanisms of Pathological aSyn Transmission"
项目一“病理性非同步传播机制”
  • 批准号:
    10452562
  • 财政年份:
    2019
  • 资助金额:
    $ 21.16万
  • 项目类别:
Project I "Mechanisms of Pathological aSyn Transmission"
项目一“病理性非同步传播机制”
  • 批准号:
    10020334
  • 财政年份:
    2019
  • 资助金额:
    $ 21.16万
  • 项目类别:
Center On Alpha-synuclein Strains In Alzheimer Disease & Related Dementias
阿尔茨海默病α-突触核蛋白菌株研究中心
  • 批准号:
    10452557
  • 财政年份:
    2019
  • 资助金额:
    $ 21.16万
  • 项目类别:
Examining neuronal resilience in a mouse model of sporadic ALS
检查散发性 ALS 小鼠模型的神经元弹性
  • 批准号:
    10610826
  • 财政年份:
    2019
  • 资助金额:
    $ 21.16万
  • 项目类别:
Center On Alpha-synuclein Strains In Alzheimer Disease & Related Dementias
阿尔茨海默病α-突触核蛋白菌株研究中心
  • 批准号:
    10373915
  • 财政年份:
    2019
  • 资助金额:
    $ 21.16万
  • 项目类别:
Project I "Mechanisms of Pathological aSyn Transmission"
项目一“病理性非同步传播机制”
  • 批准号:
    10654801
  • 财政年份:
    2019
  • 资助金额:
    $ 21.16万
  • 项目类别:
Examining neuronal resilience in a mouse model of sporadic ALS
检查散发性 ALS 小鼠模型的神经元弹性
  • 批准号:
    10381720
  • 财政年份:
    2019
  • 资助金额:
    $ 21.16万
  • 项目类别:

相似海外基金

Development and Translation Mass Spectrometry Methods to Determine BioMarkers for Parkinson's Disease and Comorbidities
确定帕金森病和合并症生物标志物的质谱方法的开发和转化
  • 批准号:
    2907463
  • 财政年份:
    2024
  • 资助金额:
    $ 21.16万
  • 项目类别:
    Studentship
Development of a predictive biomarker for Parkinson's disease
帕金森病预测生物标志物的开发
  • 批准号:
    MR/Y019415/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.16万
  • 项目类别:
    Research Grant
Promoting Parkinson's disease trial participation in rural and coastal communities
促进农村和沿海社区参与帕金森病试验
  • 批准号:
    2898794
  • 财政年份:
    2024
  • 资助金额:
    $ 21.16万
  • 项目类别:
    Studentship
The Diagnostic and Prognostic Utility of Eye Tracking in Parkinson's Disease and Related Disorders
眼动追踪在帕金森病及相关疾病中的诊断和预后效用
  • 批准号:
    479285
  • 财政年份:
    2023
  • 资助金额:
    $ 21.16万
  • 项目类别:
    Operating Grants
Neurophysiological mechanism underlying freezing of gait in Parkinson's disease: transcutaneous spinal cord stimulation for gait disturbance
帕金森病步态冻结的神经生理机制:经皮脊髓刺激治疗步态障碍
  • 批准号:
    23K10409
  • 财政年份:
    2023
  • 资助金额:
    $ 21.16万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Inhibition of cell-to-cell propagation of alpha-synuclein aggregation by glial cells and its involvement in neuropathology in Parkinson's disease.
神经胶质细胞抑制α-突触核蛋白聚集的细胞间传播及其参与帕金森病的神经病理学。
  • 批准号:
    23K06928
  • 财政年份:
    2023
  • 资助金额:
    $ 21.16万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Propagation of a-synuclein in Parkinson's disease progress
α-突触核蛋白在帕金森病进展中的传播
  • 批准号:
    22KJ2095
  • 财政年份:
    2023
  • 资助金额:
    $ 21.16万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Drug-microbiome-host interactions in Parkinson's disease
帕金森病的药物-微生物组-宿主相互作用
  • 批准号:
    2881438
  • 财政年份:
    2023
  • 资助金额:
    $ 21.16万
  • 项目类别:
    Studentship
Ordering the disordered in Parkinson's disease to derive peptide inhibitors of alpha-synuclein toxicity
命令帕金森病患者衍生出α-突触核蛋白毒性的肽抑制剂
  • 批准号:
    2884235
  • 财政年份:
    2023
  • 资助金额:
    $ 21.16万
  • 项目类别:
    Studentship
MICA: How does the pedunculopone nucleus influence treatment responses in Parkinson's disease, and can it be targeted for new treatment strategies
MICA:脚核如何影响帕金森病的治疗反应,是否可以作为新治疗策略的目标
  • 批准号:
    MR/X005267/1
  • 财政年份:
    2023
  • 资助金额:
    $ 21.16万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了